Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Company news
>
2025
>
Gossamer Bio
Gossamer Bio
Read also
ChemDiv Continues R&D Services Support for Clywedog Therapeutics
San Diego, CA — September 30, 2025 — ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry,
ChemDiv Partnership with Mondego Bio
ChemDiv Extends Discovery and Early Development Partnership with Mondego Bio on Best-in-Class PTPN2 Immuno-Oncology Program
Amgen opens new drug substance
Amgen opens new drug substance facility in North Carolina, US
BIA report
BIA report: UK biotech investment surged to £3.5bn in 2024
